title: Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
abstract: BACKGROUND
  Alterations in hemostasis have frequently been observed in patients with leukemia, and thrombotic events are well documented in patients receiving L-asparaginase (ASP) as a single agent or in combination with vincristine, prednisone (sometimes complemented by an anthracycline). The present study was designed to evaluate prospectively fibrinolytic parameters in leukemic children receiving different E. coli ASP preparations (Kyowa ASP, n = 20; Bayer ASP, n = 20), and to relate changes in the fibrinolytic system to serum ASP activity.
  
  
  METHODS
  Blood samples for coagulation studies were obtained together with serum samples for pharmacokinetic monitoring in the same venipuncture (before the first and 6th-7th doses of ASP).
  
  
  RESULTS
  Patients receiving Kyowa ASP showed significantly (0.0001) enhanced ASP-activity compared to children treated with the Bayer preparation. Significantly decreased values of fibrinogen (p < 0.001), plasminogen (p < 0.0002) and alpha 2-antiplasmin (p < 0.0003) were found in the Kyowa group, along with significantly enhanced thrombin generation (F1 + 2; p < 0.001), t-P (p < 0.01) and D-dimer levels (p < 0.05). In contrast, PAI 1 activity demonstrated no significant difference in the two E. coli ASP administered.
  
  
  CONCLUSIONS
  Changes in fibrinogen, plasminogen, alpha 2-antiplasmin and D-dimer are clearly associated with ASP activity during the course of ASP administration in children with ALL.
authors.affiliation: University Children's Hospital, Münster, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Nowak-Göttl
authors.forename: G
authors.initials: G
authors.lastname: Werber
authors.forename: D
authors.initials: D
authors.lastname: Ziemann
authors.forename: E
authors.initials: E
authors.lastname: Ahlke
authors.forename: J
authors.initials: J
authors.lastname: Boos
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D001798:Blood Proteins / Q000187:drug effects; D002648:Child; D004926:Escherichia coli / Q000201:enzymology*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D009363:Neoplasm Proteins / Q000187:drug effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies
chemical_list: D000970:Antineoplastic Agents; D001798:Blood Proteins; D009363:Neoplasm Proteins; D001215:Asparaginase